Drug Eluting Balloon Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

Drug eluting balloons are catheter-based devices coated with anti-restenotic medication that releases the drug upon inflation during angioplasty procedures. They are used primarily in coronary and peripheral artery disease to reduce the risk of vessel re-narrowing, offering an alternative to drug-eluting stents in certain lesion types and patient populations. The global market reached approximately $1.15 billion in 2025 and is expected to continue expanding as clinical evidence supporting their efficacy grows.

• •DEBs are used across coronary, peripheral, and femoropopliteal vascular territories to treat arterial blockages
• •The technology is designed to minimize restenosis while avoiding permanent implant-related complications
• •Market valuation of ~$1.15 billion in 2025 with an 8.54% projected annual growth rate

The rising global burden of cardiovascular and peripheral artery diseases, driven by aging populations, diabetes, and sedentary lifestyles, is a primary catalyst for market expansion. Clinical advantages such as reduced need for prolonged dual antiplatelet therapy and effectiveness in complex lesions, including bifurcations and in-stent restenosis, have broadened adoption. Additionally, ongoing technological refinements in balloon coatings and delivery systems are improving procedural outcomes and physician confidence.

• •Increasing prevalence of coronary artery disease and peripheral artery disease worldwide
• •Growing preference for DEBs in treating complex lesions where stents may be less effective
• •Aging global population and rising rates of lifestyle-related vascular conditions

The market is broadly segmented by product type, including coronary drug-eluting balloons, peripheral drug-eluting balloons, and other vascular applications, with coronary DEBs currently representing the largest segment. Geographically, North America leads the market due to high healthcare expenditure, advanced interventional cardiology infrastructure, and favorable reimbursement policies. Europe and the Asia-Pacific region are also significant markets, with Asia-Pacific expected to register the fastest growth owing to improving healthcare access and rising disease prevalence in countries such as China and India.

• •North America holds the largest market share, supported by established interventional cardiology networks and reimbursement frameworks
• •Asia-Pacific is anticipated to be the fastest-growing region driven by expanding healthcare infrastructure and rising vascular disease burden
• •Product segmentation includes coronary, peripheral, and femoropopliteal drug-eluting balloon categories

What are the recent trends and outlook?

Current industry trends point toward continued DEB adoption in peripheral artery disease, particularly for femoropopliteal and below-the-knee lesions, as long-term clinical data accumulate. Advances in balloon technology, including improved drug coatings, reduced vessel trauma designs, and next-generation antiproliferative agents, are expected to drive further market penetration. Over the forecast horizon, the market is likely to benefit from expanding indications, favorable comparative outcomes versus drug-eluting stents in select patient populations, and growing procedural volumes in emerging economies.

• •Expanding use of DEBs in peripheral artery disease beyond traditional coronary applications
• •Ongoing innovation in coating technologies and catheter design to enhance drug delivery and safety
• •Market projected to reach approximately $2.24 billion by 2033 based on the 8.54% CAGR trajectory